Reunion Neuroscience Appoints Sahil V. Kirpekar as President and CEO to Lead Luvesilocin Expansion

Reunion Neuroscience has installed a psychiatry-focused executive at the top of its organization as luvesilocin advances through Phase 2 trials in two additional indications, a transition that signals accelerating clinical and commercial build-out for a compound that has already generated positive postpartum depression data. Sahil V. Kirpekar, M.D., assumes the roles of President, Chief Executive Officer, and Board member effective immediately, succeeding Greg Mayes.

Dr. Kirpekar brings roughly two decades in health sciences, with nearly 15 years concentrated in psychiatry. Most recently he served as Chief Business Officer at Atai Life Sciences (now AtaiBeckley), where he directed corporate strategy, portfolio management, and financing, including oversight of the Beckley Psytech acquisition. Before that, he spent more than eight years at Otsuka Pharmaceutical, latterly as Global Head of Business Development, executing transactions across CNS, immunology, nephrology, rare diseases, and oncology. Across his career he has been responsible for transactions totaling several billion dollars in aggregate value.

For contract manufacturers and CMOs tracking capacity requirements in novel psychiatric modalities, the appointment carries a practical read: Reunion is actively running Phase 2 trials in adjustment disorder and generalized anxiety disorder alongside its postpartum depression program, meaning manufacturing demand for luvesilocin could scale across multiple indications on a compressed timeline. Clinical-stage psychedelic-inspired compounds present distinct GMP considerations around controlled-substance handling, batch documentation under 21 CFR Part 211, and supply-chain continuity that operators should be mapping now rather than at pivotal-trial readiness.

Board Chair Dr. Ansbert Gadicke of MPM BioImpact cited Dr. Kirpekar's track record in aligning development programs with future market needs as the primary rationale for the appointment. Board member Dr. Natalie Sacks of Novo Holdings acknowledged outgoing CEO Greg Mayes for establishing the foundation on which the new leadership will build.

The pace at which Reunion converts its Phase 2 readouts in adjustment disorder and generalized anxiety disorder into pivotal-stage filings will serve as the clearest near-term indicator of whether Dr. Kirpekar's commercial and business-development background translates into accelerated regulatory progress for luvesilocin.

Source: Reunion Neuroscience Inc. via GlobeNewswire, June 15, 2026.